Skip to main content

Advertisement

SpringerLink
Log in

Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B

  • Brief Report
  • Published:
Archives of Virology Aims and scope Submit manuscript

Abstract

The aim of this study was to evaluate plasmatic and urinary therapeutic drug monitoring (TDM) of tenofovir disoproxil fumarate (TDF) in a cohort of patients with chronic hepatitis B (CHB). In 68 enrolled patients, the estimated glomerular filtration rate (eGFR) was 68 mL/min in naive subjects, while in adefovir dipivoxil (ADV)-pretreated patients, it was 55.5 mL/min (p < 0.001). The HBV E genotype was associated with lower TDF levels (β = -0.698, p < 0.001). The urinary TDF concentration was associated with ADV pretreatment (β = 0.829, p < 0.001). Determination of urinary concentrations of TDF may be useful in the clinical management of older CHB patients and those with previous treatment with ADV.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver (2017) EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. https://doi.org/10.1016/j.jhep.2017.03.021

    Article  Google Scholar 

  2. Chen Y-C, Liaw Y-F (2016) Pharmacotherapeutic options for hepatitis B. Expert Opin Pharmacother 17:355–367. https://doi.org/10.1517/14656566.2016.1118056

    Article  CAS  PubMed  Google Scholar 

  3. Marcellin P, Liang J (2010) A personalized approach to optimize hepatitis B treatment in treatment-naive patients. Antivir Ther 15(Suppl 3):53–59. https://doi.org/10.3851/IMP1624

    Article  PubMed  Google Scholar 

  4. Chan L, Asriel B, Eaton EF, Wyatt CM (2018) Potential kidney toxicity from the antiviral drug tenofovir: new indications, new formulations, and a new prodrug. Curr Opin Nephrol Hypertens 27:102–112. https://doi.org/10.1097/MNH.0000000000000392

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Quesada PR, Esteban LL, García JR et al (2015) Incidence and risk factors for tenofovir-associated renal toxicity in HIV-infected patients. Int J Clin Pharm 37:865–872. https://doi.org/10.1007/s11096-015-0132-1

    Article  CAS  PubMed  Google Scholar 

  6. Maggi P, Montinaro V, Leone A et al (2015) Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. J Antimicrob Chemother 70:1150–1154. https://doi.org/10.1093/jac/dku502

    Article  CAS  PubMed  Google Scholar 

  7. Agarwal K, Brunetto M, Seto WK et al (2018) 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68:672–681. https://doi.org/10.1016/j.jhep.2017.11.039

    Article  CAS  PubMed  Google Scholar 

  8. Byrne R, Carey I, Agarwal K (2018) Tenofovir alafenamide in the treatment of chronic hepatitis B virus infection: rationale and clinical trial evidence. Ther Adv Gastroenterol 11:1756284818786108. https://doi.org/10.1177/1756284818786108

    Article  CAS  Google Scholar 

  9. Calcagno A, Fiumanò M, Zugna D et al (2019) Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization? Pharmacogenomics J 19:65–71. https://doi.org/10.1038/s41397-018-0064-y

    Article  CAS  PubMed  Google Scholar 

  10. De Nicolò A, Simiele M, Pensi D et al (2015) UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in plasma of HBV infected patients. J Pharm Biomed Anal 114:127–132. https://doi.org/10.1016/j.jpba.2015.05.016

    Article  CAS  PubMed  Google Scholar 

  11. Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V (2010) Renal toxicity associated with tenofovir use. Expert Opin Drug Saf 9:545–559. https://doi.org/10.1517/14740331003627458

    Article  CAS  PubMed  Google Scholar 

  12. Herlitz LC, Mohan S, Stokes MB et al (2010) Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities. Kidney Int 78:1171–1177. https://doi.org/10.1038/ki.2010.318

    Article  CAS  PubMed  Google Scholar 

  13. Milián L, Peris JE, Gandía P et al (2017) Tenofovir-induced toxicity in renal proximal tubular epithelial cells: involvement of mitochondria. AIDS Lond Engl 31:1679–1684. https://doi.org/10.1097/QAD.0000000000001572

    Article  CAS  Google Scholar 

  14. Zhou Y, Yang Y, Wang P et al (2019) Adefovir accumulation and nephrotoxicity in renal interstitium: Role of organic anion transporters of kidney. Life Sci 224:41–50. https://doi.org/10.1016/j.lfs.2019.03.042

    Article  CAS  PubMed  Google Scholar 

  15. Kc C (1999) Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. In: Clin. Pharmacokinet. https://antlia.med.unipmn.it:2146/10092959/. Accessed 21 Dec 2020

  16. Dai CL, Zhu M, Wang BP et al (2012) Prolonged adefovir therapy associated Fanconi syndrome and interstitial nephritis in hepatitis B. Intern Med J 42:955–957. https://doi.org/10.1111/j.1445-5994.2012.02854.x

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. Lucio Boglione and Ilaria De Benedetto contributed equally to the manuscript.

Authors and Affiliations

  1. Department of Translational Medicine (DiMET), University of Eastern Piedmont, Via Solaroli 17, 28100, Novara, Italy

    Lucio Boglione & Antonio D’Avolio

  2. Unit of Infectious Diseases, Department of Medical Sciences, University of Turin, Turin, Italy

    Ilaria De Benedetto, Valentina Dodaro, Marta Chiecchio, Amedeo De Nicolò & Giovanni Di Perri

Authors
  1. Lucio Boglione
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ilaria De Benedetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Valentina Dodaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Marta Chiecchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amedeo De Nicolò
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giovanni Di Perri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Antonio D’Avolio
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lucio Boglione.

Ethics declarations

Conflict of interest

The authors declare no conflicts of interest.

Ethical approval

The present study was approved by our local ethics committee as protocol “HBV-analogues” on 15 May 2015. This study was approved by the local ethics committee as “HBV-Analogues Study” (Prot. N°002360; 26/1/2015), and all included subjects provided written informed consent.

Additional information

Handling Editor: Michael A. Purdy.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Boglione, L., De Benedetto, I., Dodaro, V. et al. Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B. Arch Virol 167, 1669–1674 (2022). https://doi.org/10.1007/s00705-022-05466-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00705-022-05466-y

Search

Navigation